Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.

UNLABELLED: Our goal in this study was to elucidate the mechanisms by which methotrexate radiosensitizes HER2-positive human breast cancer cells to the Auger electron emitter (111)In-trastuzumab modified with nuclear-localization sequence peptides ((111)In-NLS-trastuzumab) and to compare these mecha...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Costantini, D, Villani, D, Vallis, K, Reilly, R
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	2010

Antzeko izenburuak

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
nork: Costantini, D, et al.
Argitaratua: (2008)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
nork: Costantini, D, et al.
Argitaratua: (2007)

111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
nork: Cornelissen, B, et al.
Argitaratua: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
nork: Cornelissen, B, et al.
Argitaratua: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
nork: Cornelissen, B, et al.
Argitaratua: (2012)

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
nork: Reilly, R, et al.
Argitaratua: (2006)

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
nork: Costantini, D, et al.
Argitaratua: (2010)

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
nork: McLarty, K, et al.
Argitaratua: (2009)

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
nork: Bailey, K, et al.
Argitaratua: (2007)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
nork: Mohd Nafi, SN
Argitaratua: (2014)

A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
nork: Reilly, R, et al.
Argitaratua: (2004)

Auger electron therapy using In-111-labelled F3 peptide
nork: Cornelissen, B, et al.
Argitaratua: (2011)

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
nork: McLarty, K, et al.
Argitaratua: (2009)

The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
nork: Chen, P, et al.
Argitaratua: (2001)

Transition metal compounds as cancer radiosensitizers
nork: Gill, M, et al.
Argitaratua: (2018)

Single cell S-value calculations of a stochastic cascade model for Auger-electron emitting radionuclides
nork: Vallis, K, et al.
Argitaratua: (2016)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer.
nork: Gijsen, M, et al.
Argitaratua: (2010)

Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
nork: Arshad, M, et al.
Argitaratua: (2024)

Synergistic Cytotoxic and Antimigratory Effect of Brazilein and Doxorubicin on HER2-Overexpressing Cells
nork: Handayani, Sri, et al.
Argitaratua: (2022)

Internalization of Auger electron-emitting isotopes into cancer cells: A method for spatial distribution determination of equivalent source terms
nork: Vallis, K, et al.
Argitaratua: (2016)

Beam dynamics for the NLS superconducting LINAC
nork: Bartolini, R, et al.
Argitaratua: (2010)

X-ray reverberation in NLS1
nork: Miller, L, et al.
Argitaratua: (2011)

On origin and dynamics of the discrete NLS equation /
nork: 407613 Hadzievski, Ljupco, et al.
Argitaratua: (2000)

Absorbed dose evaluation of auger electron-emitting radionuclides: impact of input decay spectra on dose point kernels and S-values
nork: Falzone, N, et al.
Argitaratua: (2017)

111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells
nork: Gill, M, et al.
Argitaratua: (2018)

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
nork: Iwata, Hiroji, et al.
Argitaratua: (2019)

On the high–low method for NLS on the hyperbolic space
nork: Staffilani, Gigliola, et al.
Argitaratua: (2021)

On long time dynamic and singularity formation of NLS
nork: Fan, Chenjie.
Argitaratua: (2017)

The identification and validation of Auger electron-emitting radiopharmaceuticals targeting telomerase for cancer therapy
nork: Jackson, M
Argitaratua: (2013)

Targeting the nucleus: an overview of Auger-electron radionuclide therapy.
nork: Cornelissen, B, et al.
Argitaratua: (2010)

Photoresists as a high spatial resolution autoradiography substrate for quantitative mapping of intra- and sub-cellular distribution of Auger electron emitting radionuclides.
nork: Falzone, N, et al.
Argitaratua: (2012)

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder
nork: Blick, C, et al.
Argitaratua: (2012)

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
nork: Blick, C, et al.
Argitaratua: (2012)

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
nork: Early Breast Cancer Trialists’ Collaborative group (EBCTCG)
Argitaratua: (2021)

Trastuzumab-associated cardiac events in the Persephone trial
nork: Earl, H, et al.
Argitaratua: (2016)

An approximate analytical solution of the Bethe equation for charged particles in the radiotherapeutic energy range.
nork: Grimes, D, et al.
Argitaratua: (2017)

Towards quantitative intra-nuclear dose mapping of auger emitting radionuclides used for targeted radiotherapy
nork: Royle, G
Argitaratua: (2016)

Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]
nork: Hasbullah, Harissa H, et al.
Argitaratua: (2018)

On the Continuum Limit for Discrete NLS with Long-Range Lattice Interactions
nork: Kirkpatrick, Kay, et al.
Argitaratua: (2013)

Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy
nork: Terry, S, et al.
Argitaratua: (2012)